StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.4
Power Rank trend -> Rising
03/27/2025 16:00:00 EST
Vertex Pharmaceuticals Inc (VRTX)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, VRTX has been trading in a range between $513.76 and $474.50 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
VRTX is trading below resistance at $516.74, about 3% to the upside. There is support at $482.28 -4% to the downside. If it can break above the resistance, it could have some more upside. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
Vertex Pharmaceuticals Inc $VRTX entered a Green zone 51 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $492.9747, a potential down side of -1.46% from the recent price of 500.28. The stock is trading 3.92% (potential upside) below its 52 week high of $519.88 and 32.4 % (potential downside) above its 52 week low of $377.85 - based on the recent price.
Company Summary
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF) It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease.
News
| Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors Vertex Pharmaceuticals (VRTX) closed at $502.55 in the latest trading session, marking a +0.45% move from the prior day. Source: Zacks Investment Research Thu, 27 Mar 2025 19:05:37 -0400 Sentiment: Neutral |
| Final Trades: Vertex Pharma, Netflix and the IYF The Investment Committee give you their stop stocks to watch for the second half. Source: CNBC Television Thu, 27 Mar 2025 17:14:21 -0400 Sentiment: Neutral |
| Biopharma firms with foreign exposure face disruption as Trump's tariffs loom The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions. Source: Proactive Investors Thu, 27 Mar 2025 13:20:27 -0400 Sentiment: Negative |
| Trump Weighs Tariffs on Ireland's Pharma Industry. How to Play the Sector. Biopharmaceutical stocks are having their time in the spotlight thanks to President Donald Trump, who vowed to take aim at Ireland's status as a pharma hub with new tariffs. Analysts at Jefferies JEF-8.32% say there is a smart way to play the sector. Source: Market Watch Thu, 27 Mar 2025 10:22:00 -0400 Sentiment: Negative |
| Trade Tracker: Steve Weiss buys Vertex Pharmaceuticals Steve Weiss, Founder and Managing Partner of Short Hills Capital Partners joins CNBC's “Halftime Report” to explain why he's buying the Pharmaceutical company Source: CNBC Television Mon, 24 Mar 2025 13:19:13 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 519.88 52 Week Low: 377.85 Beta: 0.415 50 Day MA: 474.2426 200 Day MA: 470.1869 Earnings / Revenue Trends Qtr Earnings Growth YOY: -0.056 Qtr Revenue Growth YOY: 0.157 Forward PE: 29.4985 Trailing PE: 0